GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concert Pharmaceuticals Inc (NAS:CNCE) » Definitions » Revenue

Concert Pharmaceuticals (Concert Pharmaceuticals) Revenue : $0.04 Mil (TTM As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Concert Pharmaceuticals Revenue?

Concert Pharmaceuticals's revenue for the three months ended in Sep. 2022 was $0.01 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2022 was $0.04 Mil. Concert Pharmaceuticals's Revenue per Share for the three months ended in Sep. 2022 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 was $0.00.

Warning Sign:

Concert Pharmaceuticals Inc revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Concert Pharmaceuticals was -99.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 28.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was 40.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was -16.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 11 years, Concert Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 124.70% per year. The lowest was -82.40% per year. And the median was -2.05% per year.


Concert Pharmaceuticals Revenue Historical Data

The historical data trend for Concert Pharmaceuticals's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concert Pharmaceuticals Revenue Chart

Concert Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 143.89 10.51 1.08 7.90 32.58

Concert Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 0.01 - 0.02 0.01

Competitive Comparison of Concert Pharmaceuticals's Revenue

For the Biotechnology subindustry, Concert Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concert Pharmaceuticals's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concert Pharmaceuticals's Revenue distribution charts can be found below:

* The bar in red indicates where Concert Pharmaceuticals's Revenue falls into.



Concert Pharmaceuticals Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Concert Pharmaceuticals  (NAS:CNCE) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Concert Pharmaceuticals Revenue Related Terms

Thank you for viewing the detailed overview of Concert Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Concert Pharmaceuticals (Concert Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
65 Hayden Avenue, Suite 3000N, Lexington, MA, USA, 02421
Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the currently approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.
Executives
James V Cassella officer: Chief Development Officer 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Marc A. Becker officer: CFO, PFO 175 CROSSING BLVD., 4TH FLOOR, FRAMINGHAM MA 01702
Nancy Stuart officer: Chief Operating Officer 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Jeffrey A Munsie officer: Chief Legal Officer CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON MA 02421
Roger D Tung director, officer: Chief Executive Officer 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Peter Barton Hutt director
Thomas G Auchincloss director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Richard Aldrich director 1365 MAIN STREET, WALTHAM MA 02451
Heek Christi Van director 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jesper Hoeiland director C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451
Ronald W Barrett director C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Wilfred E Jaeger director C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Meghan Fitzgerald director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511

Concert Pharmaceuticals (Concert Pharmaceuticals) Headlines

From GuruFocus

This Insider Just Sold Shares of Concert Pharmaceuticals Inc

By GuruFocus Research GuruFocus Editor 01-10-2023

Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results

By Business Wire Business Wire 08-04-2022

Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results

By Business Wire Business Wire 11-07-2022